公开(公告)号：US20230115366A1

公开(公告)日：2023-04-13

申请号：US17853573

申请日：2022-06-29

Applicant: The Regents of the University of California

Inventor： David A. Nathanson ,  Michael E. Jung ,  Jonathan Tsang ,  Lorenz Urner ,  Peter M. Clark ,  Timothy F. Cloughesy ,  Gyudong Kim

IPC: C07D491/056 ,  C07D239/94 ,  C07D239/95 ,  C07D405/04

Abstract: The present disclosure relates to compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR-mediated cancers, such as those that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

公开(公告)号：US20250145634A1

公开(公告)日：2025-05-08

申请号：US18741322

申请日：2024-06-12

Applicant: The Regents of the University of California

Inventor： David A. Nathanson ,  Michael E. Jung ,  Jonathan Tsang ,  Lorenz Urner ,  Peter M. Clark ,  Timothy F. Cloughesy ,  Gyudong Kim

IPC: C07D491/056 ,  C07D239/94 ,  C07D239/95 ,  C07D405/04

Abstract: The present disclosure relates to compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR-mediated cancers, such as those that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

公开(公告)号：US20200290978A1

公开(公告)日：2020-09-17

申请号：US16651256

申请日：2018-09-26

Applicant: The Regents of the University of California

Inventor： David A. Nathanson ,  Wilson X. Mai ,  Michael E. Jung ,  Peter M. Clark ,  Timothy F. Cloughesy ,  Gyudong Kim ,  Jonathan Tsang ,  Lorenz Urner

IPC: C07D239/95 ,  G01N33/574 ,  A61K31/517 ,  C07D491/056 ,  A61K31/519 ,  C07D405/10 ,  G01N33/50 ,  A61K31/496 ,  A61K31/40 ,  A61K45/06 ,  A61P35/00

Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

公开(公告)号：US20240058340A1

公开(公告)日：2024-02-22

申请号：US18027313

申请日：2021-09-20

Applicant: The Regents of the University of California ,  Erasca, Inc.

Inventor： Jean-Michel Vernier ,  David A. Nathanson ,  Michael E. Jung ,  Timothy F. Cloughesy ,  Lorenz Urner ,  Peter M. Clark ,  Jonathan Tsang

IPC: A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06 ,  A61P35/00 ,  C07D491/056 ,  C07D519/00 ,  G01N33/66

CPC classification number: A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06 ,  A61P35/00 ,  C07D491/056 ,  C07D519/00 ,  G01N33/66 ,  C07B2200/05 ,  G01N2800/52

Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

公开(公告)号：US20230364091A1

公开(公告)日：2023-11-16

申请号：US18027312

申请日：2021-09-20

Applicant: The Regents of the University of California

Inventor： David A. Nathanson ,  Michael E. Jung ,  Timothy F. Cloughesy ,  Lorenz Urner ,  Peter M. Clark ,  Jonathan Tsang

IPC: A61K31/519 ,  A61K31/496 ,  C07D491/056 ,  A61K31/5377 ,  A61K31/551 ,  C07D519/00 ,  A61K31/40 ,  A61K31/407 ,  A61K31/4439 ,  A61K31/45 ,  A61K31/711 ,  A61K31/635 ,  A61K31/4025 ,  A61K31/337 ,  A61K31/7105 ,  G01N33/66

CPC classification number: A61K31/519 ,  A61K31/496 ,  C07D491/056 ,  A61K31/5377 ,  A61K31/551 ,  C07D519/00 ,  A61K31/40 ,  A61K31/407 ,  A61K31/4439 ,  A61K31/45 ,  A61K31/711 ,  A61K31/635 ,  A61K31/4025 ,  A61K31/337 ,  A61K31/7105 ,  G01N33/66 ,  C07B2200/05

Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

公开(公告)号：US11377451B2

公开(公告)日：2022-07-05

申请号：US17475144

申请日：2021-09-14

Applicant: The Regents of the University of California

Inventor： David A. Nathanson ,  Michael E. Jung ,  Jonathan Tsang ,  Lorenz Urner ,  Peter M. Clark ,  Timothy F. Cloughesy ,  Gyudong Kim

IPC: C07D491/14 ,  C07D491/056 ,  C07D239/95 ,  C07D239/94 ,  C07D405/04

Abstract: The present disclosure relates to compounds, compositions and methods for treating cancer, including compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating cancer in the brain, including glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating cancers such as glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

公开(公告)号：US20220064177A1

公开(公告)日：2022-03-03

申请号：US17475144

申请日：2021-09-14

Applicant: The Regents of the University of California

Inventor： David A. Nathanson ,  Michael E. Jung ,  Jonathan Tsang ,  Lorenz Urner ,  Peter M. Clark ,  Timothy F. Cloughesy ,  Gyudong Kim

IPC: C07D491/056 ,  C07D239/95 ,  C07D405/04 ,  C07D239/94

Abstract: The present disclosure relates to compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR-mediated cancers, such as those that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.